MedMira
Tracked across 1 events · 6 articles · First seen Jun 30, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: MedMira reported increased revenue and gross profit in Q3 FY2026 compared to previous periods, but also a net loss and increased working capital deficit. The company is advancing regulatory approvals for its Multiplo Complete Syphilis Antibody Test and expanding into international markets.
Jun 30, 2026 · 6 articles
ERGEN INTELLIGENCE
Track MedMira live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard